DE602004027992D1 - In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 - Google Patents
In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135Info
- Publication number
- DE602004027992D1 DE602004027992D1 DE602004027992T DE602004027992T DE602004027992D1 DE 602004027992 D1 DE602004027992 D1 DE 602004027992D1 DE 602004027992 T DE602004027992 T DE 602004027992T DE 602004027992 T DE602004027992 T DE 602004027992T DE 602004027992 D1 DE602004027992 D1 DE 602004027992D1
- Authority
- DE
- Germany
- Prior art keywords
- glycoproteinantigen
- sima135
- metastic
- experienced
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 title 1
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000000439 tumor marker Substances 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44882803P | 2003-02-19 | 2003-02-19 | |
PCT/EP2004/001556 WO2004074481A1 (en) | 2003-02-19 | 2004-02-18 | Glycorpotein antigen sima135 expressed in metastatic human tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004027992D1 true DE602004027992D1 (de) | 2010-08-19 |
Family
ID=32908657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004027992T Expired - Lifetime DE602004027992D1 (de) | 2003-02-19 | 2004-02-18 | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 |
Country Status (13)
Country | Link |
---|---|
US (4) | US7589173B2 (de) |
EP (1) | EP1597367B1 (de) |
JP (3) | JP2007523836A (de) |
CN (1) | CN100422328C (de) |
AT (1) | ATE473279T1 (de) |
AU (1) | AU2004213568A1 (de) |
BR (1) | BRPI0407680A (de) |
CA (2) | CA2516366A1 (de) |
DE (1) | DE602004027992D1 (de) |
ES (1) | ES2349128T3 (de) |
MX (1) | MXPA05008794A (de) |
PT (1) | PT1597367E (de) |
WO (1) | WO2004074481A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10242146A1 (de) * | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
AU2004213568A1 (en) * | 2003-02-19 | 2004-09-02 | Novartis Ag | Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells |
KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
GB0324656D0 (en) | 2003-10-22 | 2003-11-26 | Celltech R&D Ltd | A protein involved in ovarian cancer |
US20080287309A1 (en) * | 2004-07-10 | 2008-11-20 | Alexion Pharmaceuticals, Inc. | Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
WO2007005502A2 (en) * | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
JP2007112734A (ja) * | 2005-10-19 | 2007-05-10 | Chugai Pharmaceut Co Ltd | 抗cdcp1抗体を含有する癌細胞増殖抑制剤 |
WO2007074133A2 (en) | 2005-12-28 | 2007-07-05 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
US8264715B2 (en) * | 2006-04-25 | 2012-09-11 | Ricoh Company, Ltd. | Approach for implementing locked printing with remote unlock on printing devices |
US20130136689A1 (en) * | 2007-06-05 | 2013-05-30 | Christian Rohlff | Proteins |
EP2121745A2 (de) * | 2007-02-26 | 2009-11-25 | Oxford Genome Sciences (UK) Limited | Proteine |
JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー/エス | インスリン誘導体を含有する薬学的製剤 |
RU2540922C2 (ru) | 2008-10-30 | 2015-02-10 | Ново Нордиск А/С | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー/エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
WO2018112334A1 (en) | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
US20220389113A1 (en) * | 2019-11-06 | 2022-12-08 | Commonwealth Scientific And Industrial Research Organisation | Binding proteins to cub domain-containing protein (cdcp1) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0539970B1 (de) * | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
US6245898B1 (en) | 1998-06-15 | 2001-06-12 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
AU5134799A (en) * | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
US20020142003A1 (en) * | 2000-07-07 | 2002-10-03 | Norbert Schweifer | Tumor-associated antigen (B345) |
EP1301533A1 (de) | 2000-07-07 | 2003-04-16 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4 |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
AU2004213568A1 (en) * | 2003-02-19 | 2004-09-02 | Novartis Ag | Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells |
WO2007134272A2 (en) * | 2006-05-12 | 2007-11-22 | Janssen Pharmaceutica N.V. | Humanized models via targeted mtagenesis with zinc finger nuclease |
-
2004
- 2004-02-18 AU AU2004213568A patent/AU2004213568A1/en not_active Abandoned
- 2004-02-18 EP EP04711993A patent/EP1597367B1/de not_active Revoked
- 2004-02-18 CA CA002516366A patent/CA2516366A1/en not_active Abandoned
- 2004-02-18 JP JP2006501880A patent/JP2007523836A/ja not_active Withdrawn
- 2004-02-18 CA CA2787820A patent/CA2787820A1/en not_active Abandoned
- 2004-02-18 WO PCT/EP2004/001556 patent/WO2004074481A1/en active Application Filing
- 2004-02-18 ES ES04711993T patent/ES2349128T3/es not_active Expired - Lifetime
- 2004-02-18 MX MXPA05008794A patent/MXPA05008794A/es active IP Right Grant
- 2004-02-18 US US10/781,564 patent/US7589173B2/en not_active Expired - Fee Related
- 2004-02-18 CN CNB2004800074635A patent/CN100422328C/zh not_active Expired - Fee Related
- 2004-02-18 DE DE602004027992T patent/DE602004027992D1/de not_active Expired - Lifetime
- 2004-02-18 AT AT04711993T patent/ATE473279T1/de active
- 2004-02-18 PT PT04711993T patent/PT1597367E/pt unknown
- 2004-02-18 BR BRPI0407680-0A patent/BRPI0407680A/pt not_active IP Right Cessation
-
2009
- 2009-09-10 US US12/584,826 patent/US20100158917A1/en not_active Abandoned
-
2010
- 2010-09-06 JP JP2010199239A patent/JP5331071B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-14 US US13/199,975 patent/US20120039891A1/en not_active Abandoned
-
2012
- 2012-10-04 US US13/573,774 patent/US20130142798A1/en not_active Abandoned
-
2013
- 2013-06-19 JP JP2013128709A patent/JP2013241416A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2349128T3 (es) | 2010-12-28 |
US7589173B2 (en) | 2009-09-15 |
JP2013241416A (ja) | 2013-12-05 |
WO2004074481A1 (en) | 2004-09-02 |
JP2011046712A (ja) | 2011-03-10 |
US20130142798A1 (en) | 2013-06-06 |
EP1597367B1 (de) | 2010-07-07 |
US20100158917A1 (en) | 2010-06-24 |
AU2004213568A1 (en) | 2004-09-02 |
BRPI0407680A (pt) | 2006-03-01 |
JP5331071B2 (ja) | 2013-10-30 |
CA2787820A1 (en) | 2004-09-02 |
JP2007523836A (ja) | 2007-08-23 |
CA2516366A1 (en) | 2004-09-02 |
ATE473279T1 (de) | 2010-07-15 |
EP1597367A1 (de) | 2005-11-23 |
CN100422328C (zh) | 2008-10-01 |
PT1597367E (pt) | 2010-09-02 |
US20120039891A1 (en) | 2012-02-16 |
MXPA05008794A (es) | 2006-03-10 |
US20040247601A1 (en) | 2004-12-09 |
CN1761750A (zh) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004027992D1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
LTPA2017022I1 (lt) | Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas | |
ATE505544T1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
ATE488530T1 (de) | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel | |
EA202091901A1 (ru) | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
ZA200707275B (en) | Antibodies that bind to EphA2 and methods of use thereof | |
CR9599A (es) | Proteinas de union a il-12/p40 | |
TW200639182A (en) | Antibody variants and uses thereof | |
EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
HK1074670A1 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
MX2007004247A (es) | Agentes de aglutinacion especifica a angiopoyetina-2. | |
WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
MX2007013108A (es) | Reactivos que enlazan ccx-ckr2. | |
DE60231971D1 (de) | Ndet, und seine verwendung zur behandlung von krebs | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
DE60030696D1 (de) | Spezifische antikörper für cyp1b1 | |
ATE478894T1 (de) | Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept | |
UY26127A1 (es) | Antígeno asociado con tumores | |
CY1113958T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |